CoChat

Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?

Open access
HAWKINS, K. A., MOHAMED, S., WOODS, S. W. · 1999 · Psychological Medicine
Cited by 120

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The recent and pending introduction of new antipsychotic medications carries the hope of a significant advance in the treatment of schizophrenia. Although the propensity of these agents to cause fewer motor side-effects than conventional neuroleptics may lead to improved compliance and clinical effectiveness, the promise of a significant impact upon the lives of patients may primarily reside in the evidence that the atypicals alleviate negative features such as emotional flattening, social withdrawal and impoverished speech. Auditory hallucinations and delusional thinking are the more dramatic expressions of illness, but these negative symptoms, along with neuropsychological deficits, are arguably more responsible for the persisting debilitation exhibited by schizophrenics (McKay, 1980; Pogue-Geile & Harrow, 1985; Breier et al. 1991; Crow, 1991; Mukherjee et al. 1991; Kane & Freeman, 1994; Perlick et al. 1992; Green, 1996; Green et al. 1997). Negative symptoms and neuropsychological deficits are minimally responsive to conventional neuroleptics (Goldberg et al. 1991; Meltzer, 1992; Lee et al. 1994; Meltzer et al. 1994), leaving schizophrenics ill-equipped to deal with the demands of normal living. The claim is often made that clozapine alleviates both negative symptoms and neurocognitive deficits (e.g. Meltzer, 1995a). Although there is hope that the newer antipsychotics will do likewise, the evidence for neurocognitive gains in particular is, so far, limited. Only a few studies of the effects of novel antipsychotics (such as risperidone, olanzapine, sertindole and related in-trial agents) on neuropsychological functioning have been undertaken. When effects have been demonstrated, their significance has remained unclear. This state of affairs is unsatisfactory, as a positive impact upon neuropsychological functioning would be of interest for more than just clinical reasons. An amelioration of cognitive deficiencies would suggest that these features are not inexorably tied to an irreversible pathology, such as gross neurodevelopmental aberrations or loss of neural tissue. Rather, such gains would suggest a treatable underlying pathophysiology, lending hope to other treatments, including cognitive rehabilitation. Since these deficits are increasingly viewed as fundamental to our conceptions of severe psychiatric illness (Goldberg et al. 1991; Green, 1996; Nuechterlein & Subotnik, 1996), neurocognitive changes might reciprocally shed light on these medications and schizophrenia. Finally, differential effects on cognition across medications should be factored into cost–benefit analyses, particularly when these effects are accompanied by broader adaptive functioning gains. Is there any reason to believe that the novel antipsychotics will significantly improve the functional capacities of schizophrenics? Several considerations are relevant, including purported action mechanisms, animal behaviour findings, neurological effects, negative symptoms effects and existing cognitive outcome data.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s0033291798006990

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 120

Metadata

Authors
HAWKINS, K. A., MOHAMED, S., & WOODS, S. W.
Venue
Psychological Medicine
Published
1999-01
Volume
29
Issue
1
Pages
1-8
ISSN
  • 0033-2917 (ISSN-L)
  • 1469-8978
OpenAlex
W2090774800
Cited by
120
References
3
FWCI
1.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.